NEW YORK, June 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inari Medical, Inc. ("Inari Medical" or the "Company") (NASDAQ: NARI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inari Medical investors who were adversely affected by alleged securities fraud between February 23, 2022 and February 28, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/inari-medical ...

On this news, the price of Inari Medical's shares fell by over $12 per share, or 21%, from a closing price of $58.26 per share on February 28, 2024 to $46.12 per share on February 29, 2024 – wiping out approximately $700 million in market capitalization in one trading day. The case is Michiana Area Electrical Workers' Pension Fund, IBEW Local 153 v. Inari Medical, Inc., et al, No. 24-cv-03686. NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investo ...

[Click here for information about joining the class action] On February 29, 2024, Inari disclosed receipt of a civil investigative demand by the U.S. Department of Justice ("DOJ") over certain payments to healthcare professionals relating to meals and consulting services, and warned that "depending on the outcome of the investigation, there may be a material impact on our business, results of operations, or financial condition." In response to the disclosure, analysts immediately downgraded the Company's st ...

LOS ANGELES, June 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ: NARI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 24, 2022 and February 28, 2024, inclusive (the "Class Period" ...

DEADLINE: July 12, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/inari-medical-inc-loss-submission-form/? id=82715&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NARI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lea ...

Inari Medical (NARI) continues to ride on the success of its ClotTriever and FlowTriever products available for treating venous thromboembolism (VTE). The adoption of these products is rising on the back of their features, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the unique characteristics of specific disease states with better effectiveness. Apart from the efficacy of the products, an attractive procedural reimbursement is also fue ...

NEW YORK, June 4, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inari Medical, Inc. ("Inari Medical" or the "Company") (NASDAQ: NARI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inari Medical investors who were adversely affected by alleged securities fraud between February 23, 2022 and February 28, 2024. Follow the link below to get more information and be contacted by a member of our team: WHY LEVI & KORSINSKY: Over the past 2 ...

According to the Complaint, Defendants repeatedly touted Inari's financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers. On February 29, 2024, Inari announced that it received a civil investigative demand by the U.S. Department of Justice ("DOJ") over certain payments to healthcare professionals relating to meals and consulting services. Inari also warned that "depending on the ...

SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 24, 2022 – Feb. 28, 2024 Lead Plaintiff Deadline: July 12, 2024 Visit: www.hbsslaw.com/investor-fraud/nari Contact the Firm Now: NARI@hbsslaw.com 844-916-0895 Inari Medical, Inc. (NARI) Class Action: Inari Medical, a medical device manufacturer, is bracing for a protracted investigation by the Department of Justice (DO ...

Core Viewpoint - A securities class action lawsuit has been filed against Inari Medical, Inc. for alleged violations of federal securities laws, including fraudulent misrepresentations and omissions regarding the company's business and operations, impacting investors significantly during the class period from February 24, 2022, to February 28, 2024 [1][3]. Group 1: Legal Proceedings - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of investors who acquired Inari Medical common stock during the specified class period [1]. - The lead plaintiff deadline for the case is set for July 12, 2024, allowing affected investors to seek representation [2][5]. - The case is titled Michiana Area Electrical Workers' Pension Fund v. Inari Medical, Inc., et al., and is pending before Judge Jennifer Hutchison Rearden [5]. Group 2: Allegations and Impact - Inari Medical disclosed a civil investigative demand from the U.S. Department of Justice related to an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, focusing on payments to healthcare professionals [3]. - Following the announcement of the investigation, Inari Medical's stock price fell by over $12 per share, a decline of 21%, from $58.26 to $46.12, resulting in a loss of approximately $700 million in market capitalization in a single trading day [4].